[1] Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer[J]. Eur Respir J, 1997, 10(11):2529-2534.
[2] Erdi YE, Rosenzweiq K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography(PET)[J]. Radiother Oncol, 2002, 62(1):51-60.
[3] Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT:the impact of 18FDG-hybrid PET fusion[J]. Int J Radiat Oncol Biol Phys, 2001, 51(4):923-931.
[4] Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):78-86.
[5] Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma:a prospective study[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):339-350.
[6] Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer[J]. Radiother Oncol, 2000, 55(3):317-324.
[7] Foo SS, Abbott DF, Lawrentschuk N, et al. Functional imaging of intratumoral hypoxia[J]. Mol Imaging Biol, 2004, 6(5):291-305.
[8] Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM[J]. Eur J Nucl Med Mol Imaging, 2003, 30(6):844-850.
[9] Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3'deoxy-3'-[(18)F] fluorothymidine ([(18)FIFLT) as a proliferation imaging tracer in humans:correlation of[(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow eytometry in human lung tumors[J]. Clin Cancer Res, 2002, 8(11):3315-3323.
[10] Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography[J]. N Engl J Med, 2000, 343(4):254-261.
[11] Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer:prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging[J]. Radiology, 2005, 236(3):1011-1019.
[12] Nehmeh SA, Erdi YE, Rosenzweig KE, et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET-medthodology and comparison with respiratory gated PET[J]. J Nucl Med, 2003, 44(10):1644-1648.
[13] Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer[J]. Med Phys, 2002, 29(3):366-371.